



BioMarker
STRATEGIES

News Release

Contact:

Jerry Parrott, President & CEO

301-938-4043 Mobile

jparrott@biomarkerstrategies.com

FOR IMMEDIATE RELEASE

June 3, 2019

BioMarker Strategies Announces that Both of Its Core Diagnostics Technologies for Solid Tumor Cancers Are Now Covered by Patents Granted in Korea

“Compositions and Methods for Prediction of Drug Sensitivity, Resistance, and Disease Progression” (KR10-1977875) for PathMAP® Functional Signaling Profile technology

“Improved Methods and Devices for Cellular Analysis” (KR10-1658245) for SnapPath® Cancer Diagnostics System technology

Rockville, MD – June 3, 2019 – BioMarker Strategies LLC today announced that the Korean Patent Office has granted a new patent covering its PathMAP® Functional Signaling Profile technology.

“PathMAP Functional Signaling Profiles are highly predictive of individual solid tumor responses to targeted therapies and combinations because they are based on the dynamic, predictive signaling information available only from live cells,” said Jerry Parrott, President and CEO, BioMarker Strategies.

PathMAP Functional Signaling Profiles are made possible by the Company’s proprietary SnapPath® Cancer Diagnostics System, which was developed specifically to enable predictive tests to guide targeted drug development and treatment selection for patients with solid tumor cancers. SnapPath is the only diagnostics system that can generate purified populations of live solid tumor cells from live, unfixed samples in an automated and standardized manner. The system preserves the molecular integrity of these living cells for *ex vivo* exposure to targeted therapies on the SnapPath System. The Korean Patent Office previously granted a patent covering the Company’s SnapPath® Cancer Diagnostics System technology in 2018.

“Patents on both of our core technologies have now been granted in the United States, Europe, Australia, Canada, Japan and Korea,” said Mr. Parrott. “These and other granted patents give us broad protection to advance our mission to enable the use of live cells to personalize drug development and treatment selection for patients with solid tumor cancers.”

**Patents Granted BioMarker Strategies for Its SnapPath® Cancer Diagnostics System:
“Improved Methods and Devices for Cellular Analysis”**

<u>Country/Region</u>	<u>Patent #</u>	<u>Issue Date</u>	<u>Expiration</u>
United States	US9121801	September 1, 2015	December 28, 2030
Europe	EP2210080	January 28, 2015	October 24, 2028
Australia	AU2008317329	January 15, 2015	October 24, 2028
Australia	AU2014277688	January 19, 2017	October 24, 2028
Canada	CA2703631	August 22, 2017	October 24, 2028
Hong Kong	HK1145878	August 14, 2015	October 24, 2028
Japan	JP6177841	July 21, 2017	October 24, 2028
Korea	KR10-1658245	September 9, 2016	October 24, 2028

**Patents Granted for the Company’s PathMAP® Functional Signaling Profile Technology:
“Compositions for Prediction of Drug Sensitivity, Resistance and Disease Progression”***

<u>Country/Region</u>	<u>Patent #</u>	<u>Issue Date</u>	<u>Expiration</u>
United States	US9766249	September 19, 2017	August 31, 2025
Europe	EP2561368	August 2, 2017	April 18, 2031
Australia	AU2011242990	May 28, 2015	April 18, 2031
Canada	CA2795362	March 20, 2018	April 18, 2031
China	ZL201180030332.9	April 13, 2018	April 18, 2031
Japan	JP6158078	June 16, 2017	April 18, 2031
Korea	KR10-1977875	May 7, 2019	April 18, 2031
Singapore	SG184507	May 6, 2015	April 18, 2031

The SnapPath and PathMAP technologies are ideally suited to assess response to targeted drugs and combinations, including combinations with Immunotherapies, in development for the treatment of solid tumor cancers.

About BioMarker Strategies

BioMarker Strategies is a privately-held molecular diagnostics company founded in 2006 at The Johns Hopkins Science & Technology Park in Baltimore, and now based in Rockville, Maryland. The Company’s mission is to help make personalized medicine more of a reality for patients with solid tumor cancers, by providing powerful new molecular tools and research services to guide targeted drug development and treatment selection for these patients. For more information about BioMarker Strategies, please see www.biomarkerstrategies.com.

Forward-Looking Statements

The information in this press release includes our projections and other forward-looking statements regarding future events. In some cases, forward-looking statements may be identified by terminology such as “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “projects,” “estimates,” “predicts,” “potential,” “continue”, etc. These statements are not guarantees of future performance or achievement and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is projected here.

###